UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

              Current Report Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

          Date of Report (Date of earliest event reported): May 2, 2006

                         Calypte Biomedical Corporation
                         ------------------------------
               (Exact name of Company as specified in its charter)

Delaware                                   000-20985               06-1226727
--------                                   ---------               ----------
(State or Other Jurisdiction)      (Commission File Number)     (I.R.S. Employer
of Incorporation)                                                Identification)

             5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035
             ------------------------------------------------------
              (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (971) 204-0282
                                                           --------------


                                       N/A
                                       ---
          (Former name or former address, if changed since last report)


|_|   Written communication pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 40.13e-4(c))

<PAGE>

Item 5.02   Departure of Directors or Principal Officers; Election of Directors;
            Appointment of Principal Officers.

(c) On May 2, 2006,  the  Company's  board of directors  appointed its Chairman,
Roger I. Gale, as Chief Executive Officer,  effective immediately.  Mr. Gale had
been serving in that capacity on an interim  basis since October 2005.  Mr. Gale
was  appointed  to the  Company's  Board of  Directors  and elected  Chairman in
November  2004.  Mr. Gale served from  October  2001 until May 2006 as Executive
Chairman of the Board of Directors of Wavecrest  Group  Enterprises  Limited,  a
United Kingdom-based  communications  service provider. He is also a founder and
director of Starnorth Limited, a communications and media consultancy. From 1999
to 2001,  he was Chairman  and  co-founder  of End2End  Wireless  Limited,  a UK
wireless access services provider.  He has previously held senior positions with
the  Asian  Development  Bank  (ADB,  Manila)  and  the  International   Finance
Corporation (IFC), the private sector arm of the World Bank in Washington,  D.C.
Mr.  Gale has also  lectured  in  economics  at the  University  of New  England
(Australia)  and Lincoln  College (New  Zealand).  He serves as a Director and a
member of the Audit Committee of Mechel Steel Group, (NYSE: MTL). Mr. Gale holds
a Master of Economics degree from the University of New England,  Australia, and
a Higher  National  Diploma from the Royal  Agricultural  College,  Cirencester,
Gloucestershire,  England.  Mr. Gale is one of two  Directors  appointed  to the
Company's  Board  pursuant to an August 2003  agreement  between the Company and
Marr  Technologies  BV  ("Marr").   Marr  is  currently  the  Company's  largest
stockholder,  holding  approximately  26% of the  Company's  outstanding  common
stock.


Item 9.01   Financial Statements and Exhibits

(c)   Exhibits

99.1  Press release dated May 8, 2006.


<PAGE>


                                   SIGNATURES

Pursuant  to the  requirement  of the  Securities  Exchange  Act  of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  Lake Oswego, Oregon
       May 8, 2006

                         Calypte Biomedical Corporation

                         By: /s/ Theodore R. Gwin
                             --------------------------
                                 Theodore R. Gwin
                                 Chief Financial Office
{"company-data": {"conformed-name": "CALYPTE BIOMEDICAL CORP", "cik": "0000899426", "assigned-sic": "3826", "irs-number": "061226727", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-32280", "film-number": "06816051"}, "business-address": {"street1": "5000 HOPYARD ROAD, SUITE 480", "city": "PLEASANTON", "state": "CA", "zip": "94588", "phone": "9257307200"}, "mail-address": {"street1": "5000 HOPYARD ROAD, SUITE 480", "city": "PLEASANTON", "state": "CA", "zip": "94588"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

              Current Report Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

          Date of Report (Date of earliest event reported): May 2, 2006

                         Calypte Biomedical Corporation
                         ------------------------------
               (Exact name of Company as specified in its charter)

Delaware                                   000-20985               06-1226727
--------                                   ---------               ----------
(State or Other Jurisdiction)      (Commission File Number)     (I.R.S. Employer
of Incorporation)                                                Identification)

             5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035
             ------------------------------------------------------
              (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (971) 204-0282
                                                           --------------

                                       N/A
                                       ---
          (Former name or former address, if changed since last report)

|_|   Written communication pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 40.13e-4(c))
Item 5.02   Departure of Directors or Principal Officers; Election of Directors;
            Appointment of Principal Officers.

(c) On May 2, 2006,  the  Company's  board of directors  appointed its Chairman,
Roger I. Gale, as Chief Executive Officer,  effective immediately.  Mr. Gale had
been serving in that capacity on an interim  basis since October 2005.  Mr. Gale
was  appointed  to the  Company's  Board of  Directors  and elected  Chairman in
November  2004.  Mr. Gale served from  October  2001 until May 2006 as Executive
Chairman of the Board of Directors of Wavecrest  Group  Enterprises  Limited,  a
United Kingdom-based  communications  service provider. He is also a founder and
director of Starnorth Limited, a communications and media consultancy. From 1999
to 2001,  he was Chairman  and  co-founder  of End2End  Wireless  Limited,  a UK
wireless access services provider.  He has previously held senior positions with
the  Asian  Development  Bank  (ADB,  Manila)  and  the  International   Finance
Corporation (IFC), the private sector arm of the World Bank in Washington,  D.C.
Mr.  Gale has also  lectured  in  economics  at the  University  of New  England
(Australia)  and Lincoln  College (New  Zealand).  He serves as a Director and a
member of the Audit Committee of Mechel Steel Group, (NYSE: MTL). Mr. Gale holds
a Master of Economics degree from the University of New England,  Australia, and
a Higher  National  Diploma from the Royal  Agricultural  College,  Cirencester,
Gloucestershire,  England.  Mr. Gale is one of two  Directors  appointed  to the
Company's  Board  pursuant to an August 2003  agreement  between the Company and
Marr  Technologies  BV  ("Marr").   Marr  is  currently  the  Company's  largest
stockholder,  holding  approximately  26% of the  Company's  outstanding  common
stock.

Item 9.01   Financial Statements and Exhibits

(c)   Exhibits

99.1  Press release dated May 8, 2006.
SIGNATURES

Pursuant  to the  requirement  of the  Securities  Exchange  Act  of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  Lake Oswego, Oregon
       May 8, 2006

                         Calypte Biomedical Corporation

                         By: /s/ Theodore R. Gwin
                             --------------------------
                                 Theodore R. Gwin
                                 Chief Financial Office